Hologic, Inc. (HOLX)
Market Cap | 15.20B |
Revenue (ttm) | 4.04B |
Net Income (ttm) | 557.10M |
Shares Out | 222.42M |
EPS (ttm) | 2.41 |
PE Ratio | 28.31 |
Forward PE | 15.50 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,116,637 |
Open | 67.62 |
Previous Close | 67.73 |
Day's Range | 67.15 - 68.38 |
52-Week Range | 51.90 - 84.39 |
Beta | 0.63 |
Analysts | Buy |
Price Target | 78.92 (+15.48%) |
Earnings Date | Nov 3, 2025 |
About HOLX
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginos... [Read more]
Financial Performance
In 2024, Hologic's revenue was $4.03 billion, a decrease of -0.00% compared to the previous year's $4.03 billion. Earnings were $789.50 million, an increase of 73.14%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for HOLX stock is "Buy." The 12-month stock price target is $78.92, which is an increase of 15.48% from the latest price.
News

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025.

Hologic Receives FDA Clearance and CE Mark for Automated Molecular Tests to Detect Common Causes of Infectious Gastroenteritis
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #Bacterial--Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Panther Fus...

New Survey Results Underscore the Need to #BustTheMyth About Mammograms
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #BCAM--New Survey Results Underscore the Need to #BustTheMyth About Mammograms.

Volition Signs Co-Marketing and Services Agreement with Hologic
HENDERSON, Nev. , Sept. 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with Holog...

Minicarm.com Named Exclusive U.S. Distributor of Hologic's Fluoroscan® Insight FD Mini C-Arm
HAUPPAUGE, N.Y. , Sept. 29, 2025 /PRNewswire/ -- Minicarm.com, a leading provider of imaging solutions for orthopedic and surgical practices, is proud to announce that it has secured an allocation of ...

New Data on Hologic's AI-Powered Mammography Technology to Be Presented at EUSOBI
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--New Data on Hologic's AI-Powered Mammography Technology to Be Presented at EUSOBI.

Blackstone and TPG revive interest in buying Hologic, source says
Private equity firms Blackstone and TPG revived their interest in acquiring medical device maker Hologic , a person close to the transaction said on Wednesday.

Hologic, Inc. (HOLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Hologic, Inc. (NASDAQ:HOLX) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Stephen MacMillan - Chairman, CEO & President Conference Call P...

Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference.

Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript
Hologic, Inc. (NASDAQ:HOLX) Q3 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Essex D. Mitchell - Chief Operating Officer Karleen M.

Hologic raises annual profit forecast on diagnostic and surgical demand
Medical equipment maker Hologic on Wednesday raised its annual profit forecast, anticipating strong demand for its molecular diagnostic devices and surgical products.

Hologic Announces Financial Results for Third Quarter of Fiscal 2025
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for Third Quarter of Fiscal 2025.

Hologic Q3 Preview: Tariff Pressure And Undervalued Stock Price, Initiate With Buy
I am initiating a Buy rating on Hologic, Inc. with a fair value of $81, as current risks are priced in. Hologic's strong diagnostic portfolio, recurring consumables revenue, and expanding assay menu s...

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025.

Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation
ARLINGTON, Va.--(BUSINESS WIRE)--NEST, an initiative of MDIC, is pleased to welcome Hologic, a leading global medical device company, to its Governance Committee.

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?
Private equity firms TPG and Blackstone BX recently bid to acquire Hologic Inc. HOLX, valuing the U.S. medical technology company at over $16 billion.

Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports
Medical equipment maker Hologic rejected a $16 billion non-binding offer from private equity firms TPG and Blackstone , the Financial Times reported on Tuesday, citing people familiar with the matter.

Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #ASCO--Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test.

Hologic to Webcast Presentations at Upcoming Investor Conferences
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentations at Upcoming Investor Conferences.

Hologic: Soft Performance, But Cheap Enough
Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term ...

Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript
Hologic, Inc. (NASDAQ:HOLX) Q2 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Mike Watts - Corporate VP, IR Steve MacMillan - Chairman, President & CEO Essex Mitchell - COO...

Medical equipment maker Hologic lowers annual profit forecast on tariff uncertainty
Medical equipment maker Hologic lowered its fiscal 2025 profit forecast, citing uncertainty around the tariffs imposed by U.S. President Donald Trump's administration, sending the company's shares dow...

Hologic Announces Financial Results for Second Quarter of Fiscal 2025
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for Second Quarter of Fiscal 2025.

Cellulite Treatment Market Trends, Growth Opportunities and Shares 2025-2030; Featuring Key Players - Hologic (Cynosure), Merz Pharma, Syneron Medical, Zimmer Aesthetics & More
Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Cellulite Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com...

Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI.